-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Bright Minds Biosciences, Lowers Price Target to $107

Benzinga·11/03/2026 11:40:37
Listen to the news
Baird analyst Joel Beatty maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform and lowers the price target from $126 to $107.